If you or a loved one takes Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML)—a rare but serious brain infection. This association has been recognized for years within the medical community, forming part of the broader understanding of immunosuppressive therapy risks. This page explains the connection, key symptoms, and what current monitoring protocols involve.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the John Cunningham virus (JCV). The FDA-approved prescribing information includes a boxed warning stating that Tysabri increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. The mechanism linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes. This mechanistic pathway is supported by the observation that risk factors for PML include the presence of anti-JCV antibodies, longer duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning explicitly states that these factors should be considered when initiating and continuing treatment. Clinical presentation of PML typically includes subacute neurological deficits such as cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on MRI findings of demyelinating lesions and detection of JCV DNA in cerebrospinal fluid via PCR. The FDA Adverse Event Reporting System (FAERS) data show that Tysabri-associated adverse events frequently include neurological symptoms such as gait disturbance, balance disorder, memory impairment, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports underscore the importance of prompt evaluation for PML in patients presenting with new or worsening neurological signs.
The adequacy of warnings regarding Tysabri and PML is a central issue in legal considerations. The prescribing information mandates that patients be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are required to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, cases of PML continue to occur, raising questions about whether the warnings are sufficient to ensure informed patient consent and timely intervention. For patients in North Carolina who have developed PML after Tysabri treatment, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For PML, the timeline between exposure to Tysabri and documented harm can vary. The boxed warning notes that risk increases with duration of therapy, and FAERS data indicate that adverse events can occur after months to years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period complicates the determination of when the statute of limitations begins to run. Patients and their families should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances, including the date of diagnosis and the date when the link to Tysabri was recognized.
In summary, the medical evidence clearly establishes that Tysabri increases the risk of PML through a well-understood mechanism, and the FDA has mandated specific warnings and monitoring protocols. However, the occurrence of PML despite these measures highlights potential gaps in risk communication. For affected individuals in North Carolina, the statute of limitations imposes a critical deadline for legal action, and the timeline from drug exposure to PML diagnosis must be carefully evaluated. Legal counsel can help navigate these complexities and determine whether a claim is timely. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962 - https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For PML, the latency period between Tysabri exposure and diagnosis can vary, so it is important to consult an attorney to determine the specific deadline for your case.
Tysabri (natalizumab) is an alpha-4 integrin antagonist that blocks lymphocyte migration into the central nervous system, reducing immune surveillance. This allows latent JC virus to reactivate and cause PML, a severe brain infection. The FDA boxed warning highlights this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.